Follows adults with relapsed lymphoma treated with tafasitamab and lenalidomide
Observes tafasitamab with lenalidomide, then alone, in adults with diffuse large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Incyte Biosciences Italy S.r.lMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Biosciences Italy S.r.l
- Trial code
- NCT06299553
- Record updated
- 22 May 2024
- Original description
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.Read full original descriptionShow less
INCB88888-040 Multicenter Prospective Real-world Observational Cohort Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.
Inclusion: Patients are aged 18 years or older; Patients with DLBCL R/R disease non-transplant eligible; Patients who will initiate the treatment with commercially available tafasitamab and lenalidomide after the ICF signature. The decision to prescribe tafasitamab must have been made prior and regardless of the enrollment of the patient in the study; Patients are able of giving the signed informed consent.
Exclusion: Concomitant participation in an interventional clinical study; Any patient in the physician's opinion from whom initial diagnosis or follow-up data is unlikely to be obtained reliably data for the purposes of this observational study; Patients who started tafasitamab treatment before signing the ICF.